rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
2000-4-18
|
pubmed:abstractText |
The effects of 6-mercaptopurine (6-MP) are mediated via its intracellular conversion to 6-thioguanine (6-TG) and 6-methylmercaptopurine (6-MMP) nucleotide metabolites, the latter genetically controlled by thiopurine methyltransferase (TPMT). We sought to determine optimal therapeutic 6-MP metabolite levels and their correlation with medication-induced toxicity and TPMT genotype.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0016-5085
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
705-13
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10734022-6-Mercaptopurine,
pubmed-meshheading:10734022-Adolescent,
pubmed-meshheading:10734022-Child,
pubmed-meshheading:10734022-Child, Preschool,
pubmed-meshheading:10734022-Dose-Response Relationship, Drug,
pubmed-meshheading:10734022-Female,
pubmed-meshheading:10734022-Genotype,
pubmed-meshheading:10734022-Humans,
pubmed-meshheading:10734022-Immunosuppressive Agents,
pubmed-meshheading:10734022-Infant,
pubmed-meshheading:10734022-Inflammatory Bowel Diseases,
pubmed-meshheading:10734022-Leukopenia,
pubmed-meshheading:10734022-Liver,
pubmed-meshheading:10734022-Male,
pubmed-meshheading:10734022-Mesalamine,
pubmed-meshheading:10734022-Methyltransferases,
pubmed-meshheading:10734022-Prospective Studies,
pubmed-meshheading:10734022-Thioguanine,
pubmed-meshheading:10734022-Treatment Outcome
|
pubmed:year |
2000
|
pubmed:articleTitle |
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
|
pubmed:affiliation |
Division of Gastroenterology and Nutrition, University of Montréal, Montréal, Québec, Canada.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|